ADMA Biologics, Inc.
ADMA
$20.11
$0.391.98%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 10.03% | 6.26% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 10.03% | 6.26% | |||
| Cost of Revenue | 7.01% | 1.96% | |||
| Gross Profit | 12.49% | 10.03% | |||
| SG&A Expenses | -1.36% | -7.88% | |||
| Depreciation & Amortization | 18.75% | 28.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.08% | -0.92% | |||
| Operating Income | 19.19% | 22.70% | |||
| Income Before Tax | 18.50% | 19.87% | |||
| Income Tax Expenses | 88.62% | -10.20% | |||
| Earnings from Continuing Operations | 6.46% | 27.19% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 6.46% | 27.19% | |||
| EBIT | 19.19% | 22.70% | |||
| EBITDA | 18.23% | 21.73% | |||
| EPS Basic | 7.76% | 25.29% | |||
| Normalized Basic EPS | 21.91% | 21.50% | |||
| EPS Diluted | 7.14% | 27.27% | |||
| Normalized Diluted EPS | 22.37% | 21.43% | |||
| Average Basic Shares Outstanding | -1.20% | 1.56% | |||
| Average Diluted Shares Outstanding | -1.59% | 1.61% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||